Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Go back to Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 4.50 -0.04 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.54 | 52 Week High | $45.34 | |||
| Open | $4.54 | 52 Week Low | $15.92 | |||
| Day High | $4.62 | P/E | 1.93 | |||
| Day Low | $4.42 | EPS | $2.33 | |||
| Volume | 1,271,242 | |||||
